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Abstract 
 
In this paper, we describe the SAR of ozonide carboxylic acid OZ78 (1) as the first part of our 
search for a trematocidal synthetic peroxide drug development candidate.  We found that 
relatively small structural changes to 1 resulted most commonly in loss of activity against 
Fasciola hepatica in vivo.  A spiroadamantane substructure and acidic functional group (or ester 
prodrug) were required for activity.  Of twenty-six new compounds administered at single 100 
mg/kg oral doses to F. hepatica-infected rats, eight had statistically significant worm burden 
reductions, seven were partially curative, and one (acyl sulfonamide 6) was completely curative 
and comparable to 1 in flukicidal efficacy.  This study also showed that the activity of 1 is 
peroxide bond-dependent suggesting that its flukicidal efficacy depends upon hemoglobin 
digestion in F. hepatica.  
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Some 250 million people are infected with parasitic trematode worms.  Of these, the most 
widespread are blood flukes of the genus Schistosoma.
1
  However, the liver flukes Fasciola 
hepatica and F. gigantica are also important pathogenic trematodes infecting an estimated 2.4-17 
million people.
2
  Fascioliasis is of considerable public health and great veterinary significance, 
and occurs worldwide, with the highest number of infected people in the Andean countries, 
Cuba, Western Europe, Egypt, and Iran.
2,3
  Triclabendazole, which has been routinely used since 
the early 1980s in veterinary medicine, is currently the sole drug used to treat human fascioliasis 
and is registered in only four countries.
4
  Evidence of drug-resistance to triclabendazole in 
veterinary medicine
5
 provides an impetus for the discovery and development of new drugs 
against fascioliasis.  In this respect, data from a recent clinical trial in Vietnam
6
 demonstrated 
that artesunate, a semisynthetic artemisinin derivative, had good efficacy in the treatment of 
human fascioliasis, although it was less effective than triclabendazole. 
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Although the semisynthetic artemisinins are best known for their powerful antimalarial 
properties, it is not surprising that they, as well as other peroxidic compounds, possess both 
antiplasmodial and trematocidal
7-9 
activities, since both plasmodia and several trematodes 
including Fasciola spp. degrade hemoglobin to generate free heme, a possible target
10
 for 
bioactive peroxides.  That the artemisinins and ozonide OZ78 (1) are so much less effective 
against the nonhemoglobin-degrading intestinal fluke Echinostoma caproni than against 
hemoglobin-degrading flukes F. hepatica, Clonorchis sinensis, and various schistosome 
species
9,11-13
 supports this hypothesis.
14
  Thus, the artemisinins and synthetic peroxides offer 
 4 
excellent starting points
15,16
 for the discovery of broad-spectrum, orally-active trematocidal 
agents that would minimize drug-resistance and lead to superior treatment and control options.  
In this paper, we describe the SAR of ozonide 1 as the first part of our search for a flukicidal 
synthetic peroxide drug development candidate. 
  
Chemistry.  Following the method of Tsandi et al.,
17 
acyl sulfonamide 6 (Scheme 1) was 
prepared by reaction of 1 with methansulfonamide in the presence of DMAP and DCC.  
Hydrazide 10 was readily prepared by reaction of the corresponding methyl ester 2 with 
hydrazine.  Ozonides 7 and 8, the glycine and taurine conjugates of 1, were synthesized by 
reaction of HOBt active ester 28
18
 with glycine ethyl ester (subsequent ester hydrolysis) and 
taurine, respectively. 
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a
Reagents and conditions: (a) MeSO2NH2, DMAP, DCC, CH2Cl2, rt, 24 h, then 1 M HCl; (b) 
hydrazine hydrate, MeOH/THF, 60 °C, 24 h; (c) glycine ethyl ester HCl, DIPEA, CH2Cl2, rt, 24 
h; (d) aq. NaOH, EtOH, then 1 M HCl to pH 5; (e) taurine, THF/aq. NaOH. 
 
Ozonide dicarboxylic acid 14 was synthesized in a five-step sequence (Scheme 2) starting from 
29,
19
 the Knoevenagel condensation product of 1,4-cyclohexanedione monoethylene ketal and 
isopropylidene malonate (Meldrum’s Acid).20  Reduction (99%), deketalization (27%), and 
esterification (37%) afforded diester ketone 30 which underwent Griesbaum coozonolysis
21
 with 
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oxime ether 31
22
 to afford diester ozonide 32 in 75% yield.  The latter was hydrolyzed to afford 
14 in high yield.  
Scheme 2
a
 
OO
O
32, X = OMe, 75%
14, X = OH,   87%
e
COX
COX
O
COOMe
COOMeO
OO
O
O
O
a, b, c
N
OMe
+
31
29 30, 18% (three steps)
d
 
 
a
Reagents and conditions: (a) 4 Å mol. sieves, pyridine, rt, 2d; (b) H2, 10% Pd-C, CH2Cl2, rt, 24 
h; (c) MeOH/Et2O, H2SO4, reflux, 12 h; (d) O3, CH2Cl2/cyclohexane, 0 °C, solid NaHCO3, 2 h; 
(e) 1 N KOH/THF, rt, 12 h, then 1 M HCl.  
 
The synthesis of ozonide 16, the monoethyl phosphonic acid isostere of 1, began with the 
synthesis of ketophosphonate diester 33 (26% yield) (Scheme 3) from 4-
(bromomethyl)cyclohexanone in an Arbuzov reaction following the method of Yamagishi et al.
23 
4-(Bromomethyl)cyclohexanone, in turn, was obtained by HCl deprotection of the corresponding 
ethylene ketal
24
 in 74% yield.  Ozonide diethyl phosphonate 34, obtained in good yield by 
Griesbaum coozonolysis
21
 between oxime ether 31
22
 and 33, was treated with potassium 
trimethylsilanolate
25
 to afford 16.   Ozonide piperidine carboxylate 17 was obtained by 
hydrolysis of its corresponding ester 36 in 84% yield; the latter was obtained by deprotection of 
BOC ozonide 35
26
 with methanesulfonic acid followed by alkylation with ethyl bromoacetate in 
90% overall yield.  Ozonide ester 39, the precursor of ozonide carboxylic acid 18, the trans 
isomer of 1, was obtained in 21% yield by Griesbaum coozonolysis
21
 of oxime ether 38 and 2-
adamantanone.  With this combination of reaction partners, cis (2) and trans (39) ester ozonides 
 6 
were produced in a ratio of 1:2.5 and 39 was purified by flash column chromatography.  In 
contrast, 2 is the major reaction product in a Griesbaum coozonolysis of oxime ether 31 and keto 
ester 37.
27
  Ozonide carboxylic acids 19 and 20, regioisomers of 1, were both obtained in a 
straightforward two-step Griesbaum coozonolysis/ester hydrolysis sequence starting from oxime 
ether 31 and the corresponding keto esters 40 and 42.  Unexpectedly, both 41 and 43 were 
formed with high diastereoselectivity and were isolated as single isomers.  Assuming the 
peroxide bond is axial and the alkyl ester substituent is equatorial,
18,27-29 
we assigned structures 
for 19 and 20 as indicated in Scheme 3, although X-ray crystallographic analysis would be 
required to substantiate this. 
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a
Reagents and conditions: (a) O3, CH2Cl2/cyclohexane, 0 °C; (b) Me3SiOK, THF, 50 °C, 4 h; (c) 
MSA, CH3CN, rt, 24 h; (d) BrCH2COOEt, aq. K2CO3/THF, rt, 6 h; (e) aq. NaOH/EtOH, rt, 2 h; 
(f) MeONH2 HCl, EtOH, pyridine, rt, 2 to 6 h; (g) 2-adamantanone, O3, CH2Cl2/cyclohexane, 0 
°C; (h) 1 N NaOH, aq. EtOH, 25 to 60 °C, 3 h, then 1 M HCl, 0 °C.   
 
Ozonide acids 21 (2.3:1 mixture of isomers) and 22 (single isomer) (Scheme 4) were obtained by 
hydrolysis of ozonide esters 45 (4:1 mixture of isomers) and 47 (9:1 mixture of isomers), which, 
in turn, were obtained by Greisbaum coozonolysis
21
 of keto ester 37
18
 and oxime ethers 44
30 
and 
46,
28
 respectively.  Based upon the axial peroxide bonds and equatorial cyclohexyl substituents 
in ozonide products from similar coozonolysis reactions,
18,27-29 
we assigned the structures for 47 
and 22 as indicated in Scheme 4.  
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a
Reagents and conditions: (a) same as (a) in Scheme 3; (b) same as (h) in Scheme 3. 
 
Fluorinated ozonide acids 23-25 (Scheme 5) were obtained in parallel five to six-step sequences 
for which the key reaction was a Griesbaum coozonolysis
21
 between fluorinated oxime ethers 51, 
57, and 61 and keto ester 37
18
 to form the corresponding ozonide esters 52, 58, and 62 in low to 
moderate yields; hydrolysis of the latter yielded 23-25 (62-99%).  Ozonide esters 58 and 62 were 
obtained as single diastereomers and were assigned as cis based on the previously observed
27
 
 8 
diastereoselectivity of the Griesbaum coozonolysis reaction.  Ozonide ester 52 was obtained as a 
3:1 ratio of diastereomers; as depicted in Scheme 5, the major isomer was assigned as trans, cis 
based on the diastereoselectivity of similar coozonolysis reactions with other 5-substituted-2-
adamantanones.
31
 The fluorinated oxime ethers 51, 57, and 61 were obtained in high overall 
yields by successive treatment of 5-hydroxy-2-adamantanone ethylene ketal (48),
32
 6-hydroxy-2-
adamantanone ethylene ketal (54), and 2,6-adamantanedione monoethylene ketal (53)
33
 with 
bis(2-methoxyethyl)aminosulfur trifluoride followed by deprotection and condensation with 
methoxylamine.  
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a
Reagents and conditions: (a) bis(2-methoxyethyl)aminosulfur trifluoride, CH2Cl2, 0 °C, 1 h; (b) 
conc. HCl, aq. acetone, rt, 1 h; (c) same as (f) in Scheme 3; (d) same as (a) in Scheme 3; (e) same 
as (g) in Scheme 3; (f) NaBH4, MeOH, 0 to 10 °C to rt, 24 h; (g) bis(2-
methoxyethyl)aminosulfur trifluoride, CH2Cl2, rt, 24 h. 
 
Triethylsilylperoxyketal ester 63, the key intermediate in the synthesis of 1,2-dioxolane 26 was 
obtained in a two-step sequence
34
 from keto ester 37 (Scheme 6).  Formation of the 
 9 
peroxycarbenium intermediate
35
 by treatment of 63 with SnCl4 in the presence of 2-
methyleneadamantane afforded 1,2-dioxolane ester 65 (40%) that was hydrolyzed to form 26 
(93%).  1,2-Dioxolane ester 65 was obtained as a single diastereomer and was assigned a cis 
configuration based on the stereochemistry observed in similar reactions.
36 
 Ketal 27, the non-
peroxidic isostere of 1, was obtained in 79% yield as a 1.3:1 mixture of isomers by p-TSA 
catalyzed condensation
14
 of 2-hydroxymethyl-2-adamantanol (66)
37
 and 2-(4-
oxocyclohexyl)acetic acid (67).  Ozonides 1-5, 9, 11-13 and 15 were obtained as previously 
described.
18,27,38
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a
Reagents and conditions: (a) 50% H2O2, I2, MeOH, rt, 24 h; (b) Et3SiOTf, Et3N, DMF, 0 °C to 
rt, 24 h; (c) 1 N SnCl4, CH2Cl2, –78 to –30 °C, 12 h; (d) 15% aq. KOH, 60 °C, 20 h; (e) p-TSA, 
CH2Cl2, rt, 4h.   
 
Activity against F. hepatica.  Efficacy data for the target compounds administered at oral doses 
of 100 mg/kg to F. hepatica-infected rats
39
 are shown in Tables 1-3.  At eight weeks post-
infection, rats were treated with single 50-100 mg/kg oral doses of target compounds prepared as 
suspensions in 7% (v/v) Tween 80 and 3% (v/v) EtOH.  At day 6 post-treatment, rats were 
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sacrificed and adult flukes were recovered from the bile ducts and livers.  Target compound 
efficacies were evaluated by comparing the mean total worm burdens of treated and untreated 
control rats.  Statistical significance was calculated using the Kruskal-Wallis test.  
 
 
Table 1 shows efficacy data for a range of acidic, neutral and weak base amide derivatives of 1.  
Of these compounds, the only one with efficacy equal to 1 was acyl sulfonamide 6, although 
methyl ester 2 and glycine conjugate 7 achieved statistically significant worm burden reductions 
and partial cures; a 50 mg/kg dose of ethyl ester 3 also produced partial cures.  The presence of 
an acidic functional group was no guarantee of good activity for these ozonides.  For example, 
hydroxamic acid 4, amphoteric acylguanidine 5, and taurine conjugate 8 were either completely 
inactive or produced marginal decreases in total worm burdens and cured no infected animals.  
Unlike 2 and 3, the alkyl ester prodrugs of 1, the primary amide (9), hydrazide (10), and 
piperazinamide (11) derivatives were inactive or only weakly active and cured no infected rats.   
 
Table 2 shows efficacy data for compounds that probe the effect of changing the position (12, 13, 
18, 19) and stereochemistry (18) of the carboxylic acid functional group of 1.  The position and 
stereochemistry of the carboxylic acid functional group in 1 seems to be optimal since removing 
(12) or extending (13) the connecting alkyl link reduced efficacy, as did changing the 
stereochemistry from cis (1) to trans (18) and changing the position of attachment of the 
carboxymethyl substituent on the cyclohexyl substructure (19, 20).  Even though the preceding 
six compounds were less effective than 1, ozonides 12, 18 and 20 were partially curative and 
achieved statistically significant worm burden reductions.  In addition, the effects of an 
additional carboxylic acid functional group (14), replacing the carboxylic acid with a monoethyl 
phosphonic acid (16) or carboxy oxamide (15), and substituting the spirocyclohexyl substructure 
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of 1 with a spiropiperidinyl in 17 were examined.  Not one of compounds 14-17 significantly 
reduced worm burden reductions, nor were they curative; the lack of efficacy of 17 is consistent 
with SAR trends of antimalarial ozonides.
26 
 
Table 3 shows efficacy data for compounds that probe the effect of replacing the spiroadamantyl 
substructure of 1 with a spirocyclohexyl (21) or bicyclo[3.3.1]nonane (22), or of fluorine 
substitution (23-25) of the spiroadamantyl substructure of 1.   The non-existent to low efficacies 
for 21 and 22 is an outcome consistent with SAR trends for antimalarial ozonides.
28 
 Target 
ozonides 23-25 were designed to slow or block potentially inactivating CYP450 metabolism of 
the distal bridgehead carbon atoms of 1 based on the known inactive CYP450 metabolites
31
 of 
arterolane (OZ277).
40 
 Although 23-25 had moderate efficacies against F. hepatica, none was 
more active than 1.   
 
The complete loss of efficacy for 27 (Table 3), the non-peroxidic isostere of 1, shows that the 
activity of 1 is peroxide bond-dependent.  The lack of efficacy for the peroxidic 1,2-dioxolane 
26, consistent with our previous data
35
 showing that 1,2-dioxolanes have very low to no 
antimalarial activity, provides additional mechanistic insight.  1,2-Dioxolanes react with Fe(II) 
primarily by two-electron vs. one-electron reduction to form inactive diol reaction products 
rather than carbon-centered radicals,
35
 the latter of which are formed by -scission reactions of 
the initially formed Fe(III) complexed oxy radicals.  These -scission reactions are accelerated 
by the adjacent oxygen atom
41
 present in ozonides (1,2,4-trioxolanes), but absent in 1,2-
dioxolanes.  
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Of twenty-six new compounds tested (Tables 1-3), eight had statistically significant worm 
burden reductions, seven were partially curative, and one (6) was completely curative.  
Compounds that were more effective in reducing worm burdens in the F. hepatica-infected rats 
also tended to result in partial cures, although ozonide ester 3 (36% worm burden reduction at 50 
mg/kg, 2/4 cures) and artesunate (30% worm burden reduction, 2/5 cures) were exceptions.  
Given that acyl sulfonamide 6 was the only compound with efficacy equal to that of 1 at the 100 
mg/kg dose, it was tested at the lower dose of 50 mg/kg and compared to existing data
12
 for 1.  
At 50 mg/kg, 1 and 6 reduced worm burdens by 53 and 17%, respectively, but only 1 cured (2/4) 
the infected rats.  Interestingly, previous SAR
18,26,29,42
 reveals that acidic ozonides have relatively 
weak antimalarial activities, so that it may be possible to identify an ozonide with selectivity for 
inhibition of F. hepatica.  However, 1 and 6 are clearly less effective than triclabendazole; at 10 
mg/kg, the latter reduced burden reduction by 95% and cured 3/4 infected rats.
16
  
 
Summary.  These data indicate that relatively small structural changes to 1 led, in most cases, to 
substantial, if not complete, loss of activity against F. hepatica in vivo.  A peroxide bond, 
spiroadamantane substructure, and acidic functional group (or prodrug) were required for 
activity.  Although 1 seems to be an ‘optimized’ ozonide structure for efficacy against F. 
hepatica, its peroxide-dependent activity suggests that, like antimalarial peroxides,
14
 its efficacy 
depends upon hemoglobin digestion in F. hepatica.  The mechanistic basis for the superior 
efficacy of ozonide acids is unclear, but it may derive from a favorable distribution of the 
unionized forms to the low pH mileau
43
 of the trematode gut, the site of hemoglobin digestion.  
Indeed, in an electron microscopy study
44
 of ex vivo F. hepatica, 1 caused extensive damage to 
the gut.  Investigation of the flukicidal properties of other peroxy heterocycles is in progress. 
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Experimental Section 
 
 
General.  Melting points are uncorrected.  
1
H and 
13
C NMR spectra were recorded on a 500 
MHz spectrometer.  All chemical shifts are reported in parts per million (ppm) and are relative to 
internal (CH3)4Si (0 ppm) for 
1
H and CDCl3 (77.0 ppm), CD3OD (49.0 ppm), or DMSO-d6 (39.7 
ppm) for 
13
C NMR.  Combustion analysis confirmed that all target compounds possessed purities 
≥ 95%.  
 
cis-Adamantane-2-spiro-3'-8'-[[[(methylsulfonyl)amino]carbonyl]methyl]-1',2',4'-
trioxaspiro[4.5]decane (6).  Ozonide 6 was synthesized following the method of Tsandi et al.
17
  
To a solution of 1 (1.61 g, 5.0 mmol), methanesulfonamide (951 mg, 10.0 mmol), and DMAP 
(611 mg, 5.0 mmol) in CH2Cl2 (40 mL) was added DCC (1.14 g, 5.5 mmol).  After 24 h, the 
reaction mixture was filtered and 1 M aq. HCl was added to the filtrate.  After the aqueous layer 
was extracted CH2Cl2 (2 x 30 mL), the combined CH2Cl2 extracts were dried over MgSO4, 
filtered, and evaporated in vacuo to produce a residue that was purified by chromatography (sg, 
10:1 CH2Cl2:MeOH) to afford 6 (1.05 g, 72%) as a white solid.  Mp 131–133 °C; 
1
H NMR 
(CDCl3) δ 1.26–1.30 (m, 3H), 1.68–1.96 (m, 20H), 2.22 (d, J = 6.4 Hz, 2H), 3.32 (s, 3H), 8.26 (s, 
1H); 
13
C NMR (CDCl3) δ 26.40, 26.79, 29.78, 32.82, 33.77, 34.74, 36.32, 36.72, 41.63, 42.88, 
108.16, 111.50, 170.96.  Anal. (C19H29NO6S) C, H, N. 
cis-Adamantane-2-spiro-3'-8'-[[[(carboxymethyl)amino]carbonyl]methyl]-1',2',4'-
trioxaspiro[4.5]decane (7).  Step 1.  To a solution of 
cis-adamantane-2-spiro-3'-8'-[[(1'H-benzotriazol-1'-yloxy)carbonyl]methyl] -1',2',4'-
trioxaspiro[4.5]decane (28)
18
 (2.00 g, 4.6 mmol) and glycine ethyl ester hydrochloride (762 mg, 
5.4 mmol) in CH2Cl2 (60 mL) was added DIPEA (1.29 g, 10 mmol).  The resulting mixture was 
 14 
stirred at rt for 2 h before quenching with water (30 mL).  After separation of the water layer, the 
organic layer was washed with water (4 x 30 mL), dried over MgSO4, filtered, and concentrated 
in vacuo.  The residue was crystallized from 1:5 EtOH:H2O to afford cis-adamantane-2-spiro-3'-
8'-[[[(ethoxycarbonylmethyl)amino]carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (1.50 g, 
81%) as a white solid.  Mp 157–159 °C; 1H NMR (CDCl3) δ 1.23–1.30 (m, 5H), 1.68–1.99 (m, 
21H), 2.13 (d, J = 6.8 Hz, 2H), 4.03 (d, J = 4.9 Hz, 2H), 4.22 (q, J = 7.3 Hz, 2H), 5.97 (brs, 1H); 
13
C NMR (CDCl3) δ 14.10, 26.42, 26.79, 29.94, 33.47, 33.92, 34.73, 36.31, 36.74, 41.29, 43.10, 
61.53, 108.50, 111.30, 169.95, 172.11.  Step 2.  To a solution of cis-adamantane-2-spiro-3'-8'-
[[[(ethoxycarbonylmethyl)amino] carbonyl]methyl]-1',2',4'-trioxaspiro[4.5]decane (1.01 g, 2.5 
mmol) in EtOH (80 mL) was added a solution of NaOH (198 mg, 5.0 mmol) in water (15 mL).  
The mixture was stirred for 16 h at rt, evaporated to give an oil, and acidified with 1 M aq. HCl 
to pH = 5.  After the aqueous phase was extracted with ethyl acetate (4 x 50 mL), the EtOAc 
extracts were combined, dried over MgSO4, filtered, and evaporated to give an oil that was 
crystallized from CHCl3 to afford 7 (752 mg, 80%) as a white solid.  Mp 146–148 °C; 
1
H NMR 
(DMSO-d6) δ 1.04–1.12 (m, 2H), 1.62–1.89 (m, 21H), 2.02 (d, J = 6.8 Hz, 2H), 3.71 (d, J = 5.9 
Hz, 2H), 8.15 (t, J = 5.9 Hz, 1H), 12.44 (brs, 1H); 
13
C NMR (DMSO-d6) δ 26.00, 26.41, 29.65, 
33.07, 33.64, 34.45, 35.94, 36.28, 40.72, 41.82, 108.62, 110.66, 171.60, 171.79. Anal. 
(C20H29NO6) C, H, N. 
cis-Adamantane-2-spiro-3'-8'-[[[(2'-sulfoethyl)amino]carbonyl]methyl]-1',2',4'-
trioxaspiro[4.5]decane sodium salt (8).  To a solution of 28
18
 (1.50 g, 3.4 mmol) and taurine 
(387 mg, 3.1 mmol) in THF (200 mL) was added a solution of NaOH (247 mg, 6.2 mmol) in 
water (15 mL).  After stirring for 24 h at rt, an additional portion of 28 (44 mg, 0.1 mmol) was 
added.  After further stirring for 24 h at rt, the solvents were removed in vacuo to produce an oil 
that was purified by reverse phase chromatography (C18, 1:1 MeOH:H2O) to afford 8 (1.23 g, 
 15 
80%) as a white solid.  Mp 154–156 °C; 1H NMR (DMSO-d6) δ 1.02–1.10 (m, 2H), 1.61–1.93 
(m, 23H), 2.53 (t, J = 7.9 Hz, 2H), 3.28 (td, J = 7.9, 6.9 Hz, 2H), 7.73 (s, 1H); 
13
C NMR 
(DMSO-d6) δ 26.02, 26.42, 29.71, 33.02, 33.66, 34.46, 35.64, 35.95, 36.30, 42.38, 50.88, 108.63, 
110.63, 170.91.  Anal. (C20H30NNaO7S) C, H, N. 
cis-Adamantane-2-spiro-3'-8'-(2'-oxo-2'-hydrazinoethyl)-1',2',4'-trioxaspiro[4.5]decane 
(10). To a stirred solution of 2 (0.68 g, 2 mmol) in MeOH (10 mL) and THF (5 mL) was added 
hydrazine monohydrate (3.0 g, 60 mmol). The resulting mixture was heated at 50–60 °C for 24 
h, then cooled to rt and concentrated.  The residue was dissolved in EtOAc (100 ml), washed 
with water (50 mL) and brine (50 mL), dried over MgSO4, and filtered. After removal of the 
solvent, the crude product was purified by crystallization from 5:1 CH2Cl2:EtOH to afford 10 
(0.56 g, 83%) as a colorless solid.  Mp 124–126 °C; 1H NMR (CDCl3) δ 1.15–1.35 (m, 2H), 
1.61–2.02 (m, 21H), 2.03 (d, J = 6.8 Hz, 2H), 3.55–4.09 (m, 2H), 6.76 (s, 1H); 13C NMR 
(CDCl3) δ 26.46, 26.85, 29.99, 33.36, 33.91, 34.77, 36.37, 36.77, 41.23, 108.43, 111.40, 172.77.  
Anal. (C18H28N2O4) C, H, N. 
cis-Adamantane-2-spiro-3'-8'-dicarboxymethyl-1',2',4'-trioxaspiro[4.5]decane (14).  Step 1.  
A mixture of 1,4-cyclohexanedione monoethylene ketal (31.2 g, 200 mmol), isopropylidene 
malonate (32.4 g, 220 mmol), molecular sieves, 4Å (9 g), and pyridine (300 mL) was stirred at rt 
for 2 d under Ar.  The reaction suspension was filtered and the filtrate was concentrated in 
vacuo.  The residue was dissolved in CH2Cl2 (500 mL), washed with 1 M HCl (2 x 150 mL) and 
water (3 x 150 mL). The CH2Cl2 layer was dried over MgSO4 and evaporated in vacuo to give 5-
(1,4-dioxaspiro[4.5]dec-8-ylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (29)
19
 (39.1 g, 69%) as a 
red powder.  
1
H NMR (CDCl3) δ 1.75 (s, 6H), 1.91 (t, J = 6.6 Hz, 4H), 3.15 (t, J = 6.6 Hz, 4H), 
4.00 (s, 4H); 
13
C NMR (CDCl3) δ 26.9, 30.5, 35.4, 64.6, 103.8, 106.9, 115.2, 160.8, 178.6.  Step 
2.  A solution of crude 29 (39.1g, 138.5 mmol) and 10% Pd-C (1.0 g) in CH2Cl2 (450 mL) was 
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hydrogenated at 500 psi at rt for 1 d. After filtration, the filtrate was concentrated in vacuo to 
give crude 5-(1,4-dioxaspiro[4.5]dec-8-yl)-2,2-dimethyl-1,3-dioxane-4,6-dione (38.8 g, 99%) 
which was used for the next step.  An analytical sample was obtained by flash chromatography 
(sg, 50% ether in hexane) as a yellow powder.  Mp 145–148 °C dec.; 1H NMR (CDCl3) δ 1.55–
1.65 (m, 4H), 1.75 (s, 3H), 1.77 (s, 3H), 1.80 (s, 1H), 1.82 (s, 1H), 1.97–2.05 (m, 2H), 2.41–2.46 
(m, 1H), 3.45 (d, J = 2.9 Hz, 1H), 3.95 (s, 4H); 
13
C NMR (CDCl3) δ 26.4, 27.4, 28.2, 34.7, 37.6, 
50.2, 64.2, 64.3, 104.8, 107.8, 164.8.  Step 3.  A solution of 5-(1,4-dioxaspiro[4.5]dec-8-yl)-2,2-
dimethyl 1,3-dioxane-4,6-dione (38.8 g, 136.6 mmol) and pyridinium p-toluenesulfonate (5.0 g, 
20 mmol) in acetone (400 mL) was refluxed for 20 h.  The reaction solution was concentrated 
and then dissolved in CH2Cl2 (300 mL), washed with water (3 x 100 mL), dried over MgSO4, 
and evaporated to dryness.  Due to the poor yield of the deprotection and the difficulty of 
separation, the above process was repeated four times to produce crude 5-(4-oxocyclohexyl)-2,2-
dimethyl-1,3-dioxane-4,6-dione (9.0 g, 27%) which was used for the next step.  An analytical 
sample was obtained by flash chromatography (sg, 60% ether in hexane) as a white powder.  Mp 
152–154 °C dec.; 1H NMR (CDCl3) δ 1.77 (s, 3H), 1.81 (s, 3H), 1.94–1.99 (m, 2H), 2.18–2.27 
(m, 2H), 2.37–2.48 (m, 4H), 2.88–2.95 (m, 1H), 3.61 (d, J = 2.9 Hz, 1H); 13C NMR (CDCl3) δ 
27.0, 28.1, 28.2, 36.2, 40.7, 49.8, 105.0, 164.3 and 209.9.  Step 4.  A solution of 5-(4-
oxocyclohexyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (9.0 g, 37.5 mmol), MeOH (300 mL), Et2O 
(300 mL) and conc. H2SO4 (2.0 mL, 37.6 mmol) was refluxed overnight.  The reaction mixture 
was cooled to rt and concentrated in vacuo.  The residue was dissolved in CH2Cl2 (150 mL) and 
washed with water (3 x 100 mL).  The CH2Cl2 layer was dried over MgSO4, filtered, and 
evaporated to dryness. The residue was purified by flash chromatography (sg, 50% ether in 
hexane) to give 4-[bis(methoxycarbonyl)methyl]cyclohexanone (30) (3.2 g, 37%) as a white 
solid.  Mp 59–60 °C; 1H NMR (CDCl3) δ 1.53-1.61 (m, 2H), 2.06–2.09 (m, 2H), 2.39–2.42 (m, 
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4H), 2.54–2.60 (m, 1H), 3.33 (d, J = 8.8 Hz,1H), 3.76 (s, 6H); 13C NMR (CDCl3) δ 29.9, 35.8, 
40.1, 52.4, 56.1, 168.4, 210.2.  Step 5.  A suspension of 30 (3.2 g, 14 mmol), O-methyl 2-
adamantanone oxime (31)
22
 (5.0 g, 28 mmol), NaHCO3 (no product was formed without the 
addition of solid NaHCO3) (1.7 g, 20 mmol) in CH2Cl2 (80 mL) and cyclohexane (240 mL) was 
treated with ozone at 0 °C for 2 h.  The reaction solution was concentrated and the residue was 
purified by flash chromatography (sg, 6% ether in hexane) to give cis-adamantane-2-spiro-3'-8'-
[bis(methoxycarbonyl)methyl]-1',2',4'-trioxaspiro[4.5]decane (32) (4.2g, 75%) as colorless 
crystals.  Mp 94–95 °C (ethanol); 1H NMR (CDCl3) δ 1.29–1.37 (m, 2H), 1.68–1.99 (m, 20H), 
2.09–2.16 (m, 1H), 3.19 (d, J = 8.8 Hz, 1H), 3.73 (s, 6H); 13C NMR (CDCl3) δ 26.4, 26.8, 27.7, 
33.7, 34.7, 36.2, 36.3, 36.7, 52.4, 56.9, 108.0, 111.4 and 168.9.  Step 6.  To a solution of 32 (1.0 
g, 2.5 mmol) in THF (50 mL) was added a solution of KOH (1.12 g, 20 mmol) in H2O (3.0 mL).  
After stirring at rt for 12 h, the reaction solution was concentrated. The residue was dissolved in 
EtOAc (100 mL) and H2O (50 ml) and acidified with 1 M HCl to pH = 2.  The EtOAc layer was 
separated, washed with H2O (3 x 50 mL), dried over MgSO4, and evaporated in vacuo to give cis-
adamantane-2-spiro-3'-8'-(dicarboxymethyl)-1',2',4'-trioxaspiro[4.5]decane (14) (0.81g, 87%) as 
a white powder.  Mp 152–153 °C dec.; 1H NMR (DMSO-d6) δ 1.16–1.25 (m, 2H), 1.65–1.93 (m, 
21H), 3.02 (d, J = 8.8 Hz, 1H), 12.7 (s, 2H); 
13
C NMR (DMSO-d6) δ 26.0, 26.5, 27.5, 33.6, 34.5, 
35.3, 36.0, 36.3, 57.1, 108.4, 110.8, 170.2.  Anal. (C19H26O7) C, H.  
cis-Adamantane-2-spiro-3'-8'-[[(ethoxy)hydroxyphosphinyl]methyl]-1',2',4'-
trioxaspiro[4.5]decane potassium salt (16).  Step 1.  A solution of 8-(bromomethyl)-1,4-
dioxaspiro[4.5]decane
24
 (10 g, 42.5 mmol) in EtOH (70 mL) and 6 M aq. HCl (15 mL, 90 mmol) 
was stirred overnight at rt.  After addition of saturated aq. NaHCO3 to bring the pH to 8, most of 
the solvents were removed in vacuo and water (100 mL) and ether (100 mL) were added.  After 
separation of the ether layer, the aqueous phase was extracted with ether (3 x 100 mL).  The 
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combined organic phases were dried and evaporated to give an oil that was purified by sg 
chromatography (sg, 10% EtOAc in hexane) to afford 4-(bromomethyl)cyclohexanone (6.0 g, 
74%) as a colorless oil.  
1
H NMR (CDCl3) δ 1.51-1.59 (m, 2H), 2.11-2.18 (m, 1H), 2.20-2.24 (m, 
3H), 2.34-2.45 (m, 4H), 3.39 (d, J = 6.3 Hz, 2H); 
13
C NMR (CDCl3) δ 31.00, 37.83, 38.29, 
40.02, 210.74.  Step 2.  According to the method of Yamagishi et al.,
23
 a mixture of 4-
(bromomethyl)cyclohexanone (3.0 g, 15.7 mmol) and triethyl phosphite (10.4 g, 62.8 mmol) was 
heated to 170 °C for 8 h.  After cooling, saturated aq. NaHCO3 was added to raise the pH to 8. 
The aq. phase was extracted with CH2Cl2 (3 x 100 mL).  The combined organic extracts were 
dried with MgSO4, filtered, and evaporated to give an oil that was purified with chromatography 
(sg, 50% EtOAc and hexane to 100% EtOAc) to afford diethyl [(4-
oxocyclohexyl)methyl]phosphonate (33) (1.0 g, 26%). 
1
H NMR (CDCl3) δ 1.33-1.36 (t, J = 7.3 
Hz, 6H), 1.52-1.56 (m, 2H), 1.75-1.80 (dd, J = 18.6, 7.4 Hz, 1H), 2.23-2.26 (m, 3H), 2.37-2.40 
(m, 4H), 4.08-4.16 (m, 4H); 
13
C NMR (CDCl3) δ 16.46 (d, J = 5.8 Hz), 31.21 (d, J = 3.8 Hz), 
31.54 (d, J = 140.6 Hz), 33.79 (d, J = 11.0 Hz), 40.54, 61.51 (d, J = 6.7 Hz).  Step 3.  A solution 
of 31
22
 (11.06 g, 61.7 mmol) and 33 (7.0 g, 41.1 mmol) in cyclohexane (200 mL) and CH2Cl2 
(40 mL) was treated with ozone following the method of Dong et al.
 28
  After removal of solvents 
in vacuo, the crude product was purified by chromatography (sg, 50% EtOAc in hexane) to 
afford cis-adamantane-2-spiro-3'-8'-[(diethoxyphosphinyl)methyl]-1',2',4'-trioxaspiro[4.5]decane 
(34) (10.83 g, 78%) as an oil.  
1
H NMR (CDCl3) δ 1.29-1.34 (m, 8H), 1.65-1.99 (m, 23H), 4.04-
4.13 (m, 4H); 
13
C NMR (CDCl3) δ 16.44 (d, J = 5.0 Hz), 26.47, 26.86, 31.15, 31.36 (d, J = 11.4 
Hz), 32.10 (d, J = 133.2 Hz), 33.96, 34.77, 36.37, 36.79, 61.37 (d, J = 6.4 Hz), 108.27, 111.35.  
Step 4.  According to the method of Dziemidowicz et al.,
25
 a mixture of 34 (333 mg, 0.8 mmol) 
and potassium trimethylsilanolate (412 mg, 3.2 mmol) in anhydrous THF (12 mL) was stirred at 
50 °C for 4 h.  Removal of the solvent gave a residue that was purified by reverse phase 
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chromatography (C18, 1:1 CH3OH:H2O) to afford 16 (264 mg, 85%) as a white solid.  Mp 160–
162 °C; 
1
H NMR (CDCl3) δ 1.21–1.23 (m, 5H), 1.44–1.48 (m, 2H), 1.61-1.99 (m, 21H), 3.81 (m, 
2H); 
13
C NMR (CDCl3) δ 16.66 (d, J = 6.7 Hz), 26.45, 26.84, 31.49 (d, J = 9.6 Hz), 32.10 (d, J = 
2.2 Hz), 33.00 (d, J = 130.0 Hz), 34.10, 34.73, 36.35, 36.77, 60.28 (d, J = 4.6 Hz), 108.60, 
111.11.  Anal. (C19H30KO6P) C, H. 
Adamantane-2-spiro-3'-8'-carboxymethyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane sodium salt 
(17).  Step 1.  To a suspension of adamantane-2-spiro-3'-8'-t-butoxycarbonyl-1',2',4'-trioxa-8'-
azaspiro[4.5]decane (35)
26
 (1.462 g, 4.0 mmol) in THF (10 mL) was added dropwise a solution 
of methanesulfonic acid (1.54 g, 16.0 mmol) in CH3CN (2 mL) at rt and the mixture was stirred 
at rt for 24 h.  A solution of K2CO3 (2.211 g, 16.0 mmol) in H2O (6 mL) and a solution of ethyl 
bromoacetate (802 mg, 4.8 mmol) in THF (12 mL) were added.  After the reaction was stirred 
for 6 h, the solvents were removed and the residue was diluted with EtOAc (40 mL) and H2O (30 
mL).  After phase separation, the aqueous phase was extracted with EtOAc (3 x 30 mL).  The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo.  The crude 
product was purified by sg chromatography (sg, 20% EtOAc in hexane) to afford adamantane-2-
spiro-3'-8'-ethoxycarbonylmethyl-1',2',4'-trioxa-8'-azaspiro[4.5]decane (36) (1.26 g, 90 %) as an 
oil.  
1
H NMR (CDCl3) δ 1.28 (t, J = 6.8 Hz, 3H), 1.67-2.03 (m, 18H), 2.58-2.62 (m, 2H), 2.71-
2.75 (m, 2H), 3.23 (s, 2H), 4.19 (q, J = 6.8 Hz, 2H); 
13
C NMR (CDCl3) δ 14.07, 26.26, 26.66, 
34.08, 34.54, 34.60, 36.17, 36.56, 50.96, 58.94, 60.43, 106.44, 111.47, 170.21.  Step 2.  To a 
solution of 36 (517 mg, 1.47 mmol) in EtOH (50 mL) was added a solution of NaOH (117 mg, 
2.94 mmol) in water (10 mL).  After the mixture was stirred for at rt for 2 h, the resulting 
precipitate was collected by filtration, washed with H2O (5 mL), and dried in vacuo at 40 °C to 
give 17 (305 mg, 84%) as a white solid.  Mp 140–142 °C; 1H NMR (CD3OD) δ 1.71–2.05 (m, 
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18H), 2.56 (m, 2H), 2.67 (m, 2H), 2.98 (s, 2H); 
13
C NMR (CD3OD) δ 27.96, 28.36, 35.06, 35.75, 
35.83, 37.81, 37.83, 52.38, 63.29, 108.06, 112.57, 177.62.  Anal. (C17H24NNaO5) C, H, N. 
trans-Adamantane-2-spiro-3'-8'-carboxymethyl-1',2',4'-trioxaspiro[4.5]decane (18).  Step 1.  
To a solution of methyl 2-(4-oxocyclohexyl)acetate (37) (5.106 g, 30 mmol) in EtOH (100 mL) 
was added pyridine (3.559 g, 45 mmol) followed by methoxylamine hydrochloride (2.756 g, 33 
mmol).  The reaction mixture was stirred at rt for 4.5 h, concentrated in vacuo, and diluted with 
CH2Cl2 (50 mL) and water (50 mL).  The organic phase was separated, and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with 1 M 
HCl (40 mL), saturated aqueous NaHCO3 (40 mL) and brine (40 mL), and dried over MgSO4.  
Removal of the solvents in vacuo afforded methyl 2-[4-(methoxyimino)cyclohexyl]acetate (38) 
(5.02 g, 84%) as an oil. 
1
H NMR (CDCl3) δ 1.12–1.28 (m, 2H), 1.68–2.20 (m, 6H), 2.26 (d, J = 
7.3 Hz, 2H), 2.37–2.41 (m, 1H), 3.16–3.21 (m, 1H), 3.68 (s, 3H) , 3.81 (s, 3H); 13C NMR 
(CDCl3) δ 23.96, 31.09, 31.35, 32.58, 33.85, 40.50, 51.47, 60.96, 158.88, 172.92.  Step 2.  A 
solution of 2-adamantanone (2.25 g, 14.4 mmol) and 38 (1.91 g, 9.59 mmol) in cyclohexane (50 
mL) and CH2Cl2 (10 mL) was treated with ozone according to the method of Dong et al.
28
 After 
removal of the solvents in vacuo, the crude product was purified by flash chromatography (sg, 
100:1 hexane:ethyl acetate) to afford trans-adamantane-2-spiro-3'-8'- methoxycarbonylmethyl-
1',2',4'-trioxaspiro[4.5]decane (39) (680 mg, 21%) as an oil.  
1
H NMR (CDCl3) δ 1.35-1.43 (m, 
2H), 1.58-2.03 (m, 21H), 2.27 (d, J = 6.8 Hz, 2H), 3.67 (s, 3H); 
13
C NMR (125.7 MHz, CDCl3) δ 
26.38, 26.81, 29.65, 33.27, 33.61, 34.64, 34.83, 36.28, 36.70, 40.41, 51.43, 108.35, 111.51, 
173.19.  Step 3.  To a solution of 39 (402 mg, 1.2 mmol) in EtOH (10 mL) was added a solution 
of NaOH (143 mg, 3.6 mmol) in water (3 mL). The mixture was stirred at 60 °C for 3 h and 
evaporated to give an oil.  The residue was cooled to 0 °C and treated with 1 M HCl to pH = 3.  
The resulting solid was filtered, washed with water and dried in vacuo to afford 18 (346 mg, 
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90%) as a white solid.  Mp 144–146 °C; 1H NMR (CDCl3) δ 1.38–1.45 (m, 2H), 1.60–2.03 (m, 
21H), 2.31 (d, J = 6.8 Hz, 2H); 
13
C NMR (CDCl3) δ 26.43, 26.85, 29.66, 33.10, 33.65, 34.70, 
34.88, 36.32, 36.74, 40.31, 108.33, 111.65, 178.66.  Anal. (C18H26O5) C, H. 
cis-adamantane-2-spiro-3'-6'-carboxymethyl-1',2',4'-trioxaspiro[4.5]decane (19).  Step 1.  A 
solution of O-methyl 2-adamantanone oxime (31)
22
 (896 mg, 5.0 mmol) and ethyl 2-(2-
oxocyclohexyl)acetate (40) (1.38 g, 7.5 mmol) in cyclohexane (30 mL) and CH2Cl2 (6 mL) was 
treated with ozone according to the method of Dong et al.
28
  After removal of the solvents in 
vacuo, the crude product was purified by flash chromatography (sg, 40:1 hexane:ethyl acetate) to 
afford cis-adamantane-2-spiro-3'-6'-ethoxycarbonylmethyl-1',2',4'-trioxaspiro[4.5]decane (41) 
(380 mg, 22%) as an oil.  
1
H NMR (CDCl3) δ 1.25–1.31 (m, 5H), 1.40–2.40 (m, 23H), 2.76 (dd, 
J = 15.6, 2.4 Hz, 1H), 4.12-4.18 (m, 2H); 
13
C NMR (CDCl3) δ 23.50, 26.18, 26.59, 27.27, 33.80, 
33.94, 34.57, 35.16, 35.65, 36.10, 36.52, 36.73, 39.07, 39.26, 46.77, 60.18, 109.58, 111.26, 
172.98.  Step 2.  To a solution of 41 (350 mg, 1.0 mmol) in EtOH (8 mL) was added a solution 
of NaOH (120 mg, 3.0 mmol) in water (3 mL).  The mixture was stirred at rt for 3 h, and 
concentrated in vacuo to afford an oil that was cooled to 0 °C and treated with 1 M HCl to pH = 
3.  The resulting solid was filtered, washed with water, and dried in vacuo to afford 19 (320 mg, 
93%) as a white solid.  Mp 66–69 °C; 1H NMR (CDCl3) δ 1.29–1.39 (m, 2H), 1.44–2.37 (m, 
23H), 2.84 (dd, J = 6.1, 3.9 Hz, 1H); 
13
C NMR (CDCl3) δ 23.61, 24.30, 26.29, 26.72, 29.66, 
33.80, 34.07, 34.72, 34.90, 35.34, 35.83, 36.63, 36.89, 39.24, 109.65, 111.62, 178.90.  Anal. 
(C18H26O5) C, H. 
trans-adamantane-2-spiro-3'-7'-carboxymethyl-1',2',4'-trioxaspiro[4.5]decane (20).  Step 1.  
A solution of 31
22
 (1.44 g, 8.0 mmol) and methyl 2-(3-oxocyclohexyl)acetate (42)
45
 (1.14 g, 6.7 
mmol) in cyclohexane (30 mL) and CH2Cl2 (10 mL) was treated with ozone according to the 
method of Dong et al.
28
 After removal of the solvents in vacuo, the crude product was purified 
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by column chromatography (sg, 50:1 hexane:ethyl acetate) to afford trans-adamantane-2-spiro-
3'-7'-methoxycarbonylmethyl-1',2',4'-trioxaspiro[4.5]decane (43) (998 mg, 45%) as an oil.  
1
H 
NMR (CDCl3) δ 0.93–1.00 (m, 1H), 1.40–2.09 (m, 22H), 2.20–2.29 (m, 2H), 3.66 (s, 3H); 
13
C 
NMR (CDCl3)  22.44, 26.30, 26.70, 30.76, 32.32, 34.02, 34.56, 34.59, 36.20, 36.58, 40.38, 
40.70, 51.16, 108.44, 110.99, 172.39.  Step 2.  To a solution of 43 (627 mg, 1.8 mmol) in EtOH 
(16 mL) was added a solution of NaOH (224 mg, 5.6 mmol) in water (4 mL) and the mixture 
was stirred at 60 °C for 3 h.  Removal of the solvents afforded an oil that was cooled to 0 °C and 
treated with 1 M HCl to pH = 3.  The resulting solid was filtered, washed with water, and dried 
in vacuo to afford 20 (567 mg, 94%) as a white solid.  Mp 66–68 °C; 1H NMR (CDCl3) δ 0.95–
1.02 (m, 1H), 1.42–2.08 (m, 22H), 2.22–2.33 (m, 2H); 13C NMR (CDCl3) δ 22.61, 26.44, 26.83, 
30.86, 32.29, 34.18, 34.76, 34.78, 36.35, 36.76, 40.53, 40.96, 108.65, 111.35, 178.46.  Anal. 
(C18H26O5) C, H. 
3-Carboxymethyl-7,14,15-trioxadispiro[5.1.5.2]pentadecane (21).  Step 1.  A solution of O-
methyl cyclohexanone oxime (44)
30
 (2.16 g, 17 mmol) and 37 (3.47 g, 20.4 mmol) in 
cyclohexane (120 mL) and CH2Cl2 (30 mL) was treated with ozone following the method of 
Dong et al.
28
  After removal of solvents in vacuo, the crude product was purified by 
chromatography (sg, 4% EtOAc in hexane) followed by crystallization from cold MeOH to 
afford 3-methoxycarbonylmethyl-7,14,15-trioxadispiro[5.1.5.2]pentadecane (45) (2.4 g, 50%, 
4:1 mixture of two isomers based on the 
1
H NMR doublets at 2.22 and 2.26) as a white solid.  
Mp 110–112 °C; 1H NMR (CDCl3) δ 1.27 (m, 2H), 1.36 (m, 1H), 1.43 (m, 1H), 1.56-1.82 (m, 
13H), 1.94 (d, J = 15.6 Hz, 2H), 2.22 (d, J = 7.5 Hz, 1.6H), 2.26 (d, J = 7.0 Hz, 0.4H), 3.67 (s, 
3H); 
13
C NMR (CDCl3) δ 22.46, 22.58, 23.72, 23.77, 24.82, 29.55, 29.84, 33.08, 33.22, 33.50, 
33.76, 34.54, 40.36, 40.59, 51.46, 108.32, 108.86, 109.24, 171.11, 173.21.  Step 2.  To a solution 
of 45 (678 mg, 2.24 mmol) in EtOH (50 mL) was added a solution of NaOH (180 mg, 4.48 
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mmol) in water (10 mL).  The mixture was stirred at rt for 12 h, cooled to 0 °C, and treated with 
1 M aq. HCl (5 mL) and H2O (50 mL).  The precipitate was collected by filtration, washed with 
50% aq. EtOH (10 mL), and dried in vacuo at 40 °C to give 21 (450 mg, 74%, 2.3:1 mixture of 
two isomers based on the 
1
H NMR doublets at 2.27 and 2.30) as a colorless solid.  Mp 144–146 
°C; 
1
H NMR (CDCl3) δ 1.24–1.47 (m, 4H), 1.54–1.95 (m, 15H), 2.27 (d, J = 6.8 Hz, 1.4H), 2.30 
(d, J = 6.8 Hz, 0.6H); 
13
C NMR (CDCl3) δ 23.74, 23.79, 24.84, 24.87, 29.52, 29.80, 32.88, 33.01, 
33.51, 33.76, 34.56, 40.28, 40.41, 40.51, 108.27, 108.28, 108.96, 109.33, 178.76.  Anal. 
(C14H22O5) C, H. 
Bicyclo[3.3.1]nonane-9-spiro-3'-8'-carboxymethyl-1',2',4'-trioxaspiro[4.5]decane (22).  Step 
1.  A solution of O-methyl bicyclo[3.3.1]nonan-9-one oxime (46)
28
 (792 mg, 4.7 mmol) and 37 
(1.21 g, 7.1 mmol) in cyclohexane (30 mL) and CH2Cl2 (50 mL) was treated with ozone 
following the method of Dong et al.
28
  After removal of the solvents, the crude product was 
purified by column chromatography (sg, 50:1 hexane:ethyl acetate) to afford 
bicyclo[3.3.1]nonane-9-spiro-3'-8'-methoxycarbonylmethyl-1',2',4'-trioxaspiro[4.5]decane (47) 
(807 mg, 53%) as a white solid.  Mp 82–84 °C; 1H NMR (CDCl3) δ 1.22–2.06 (m, 23H), 2.22 (d, 
J = 7.3 Hz, 2H), 3.67 (s, 3H); 
13
C NMR (CDCl3) 20.41, 20.82, 29.33, 29.52, 29.87, 33.10, 
33.94, 36.20, 40.60, 51.40, 108.27, 111.22, 173.15.  Step 2.  To a solution of 47 (785 mg, 2.4 
mmol) in EtOH (20 mL) was added a solution of NaOH (290 mg, 7.3 mmol) in water (3 mL).  
The mixture was stirred at 60 °C for 3 h, evaporated to give an oil, cooled to 0 °C, and treated 
with 1 M HCl to pH = 3.  The resulting solid was filtered, washed with water, and dried in vacuo 
to afford 22 (651 mg, 87%) as a white solid.  Mp 146–148 °C; 1H NMR (CDCl3) δ 1.25–1.33 (m, 
2H), 1.44–1.52 (m, 2H), 1.64–2.07 (m, 19H), 2.27 (d, J = 7.3 Hz, 2H); 13C NMR (CDCl3) δ 
20.44, 20.84, 29.36, 29.54, 29.84, 32.91, 33.95, 36.21, 40.55, 108.24, 111.35, 178.79.  Anal. 
(C17H26O5) C, H.  
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trans,cis-5-Fluoroadamantane-2-spiro-3'-8'-carboxymethyl-1',2',4'-trioxaspiro[4.5]decane 
(23).  Step 1.  To a stirred solution of 5-hydroxy-2-adamantanone ethylene ketal (48)
32
 (100 mg, 
0.5 mmol) in CH2Cl2 (6 mL) at 0 °C was added bis(2-methoxyethyl)aminosulfur trifluoride (158 
mg, 0.7 mmol).  After 1 h of stirring, the reaction was quenched with water (2 mL) and the aq. 
phase was extracted with CH2Cl2 (2 x 15 mL).  The combined organic layers were dried with 
MgSO4, filtered, and concentrated in vacuo to afford a residue that was purified by 
crystallization from 1:1 MeOH:H2O to afford 5-fluoro-2-adamantanone ethylene ketal (49) (81 
mg, 80%) as a white solid.  Mp 44–46 °C;  1H NMR (CDCl3)  1.55–1.57 (d, 2H), 1.73–1.75 (m, 
2H), 1.89–1.92 (m, 4H), 2.01 (s, 2H), 2.18–2.22 (m, 3H), 3.92–3.98 (m, 4H); 13C NMR (CDCl3) 
 29.80 (d, J = 10.1 Hz), 33.23 (d, J = 1.9 Hz), 38.76 (d, J = 10.6 Hz), 39.39 (d, J = 19.2 Hz), 
42.30 (d, J = 16.8 Hz), 64.32, 64.48, 91.56 (d, J = 183.8 Hz), 109.74.  Step 2.  To a solution of 
49 in 2:1 acetone:water (12 mL) was added conc. HCl (4 mL) and the reaction mixture was 
stirred for 1 h at rt before removal of the solvents in vacuo.  CH2Cl2 (6 mL) and water (6 mL) 
were added and the two phases were separated followed by extraction of the aq. phase with 
CH2Cl2 (2 x 4 mL). The combined organic layers were dried over MgSO4 and the solvent 
removed in vacuo to afford 5-fluoro-2-adamantanone (50) (55 mg, 86%) as a colorless solid.  Mp 
269–271 °C; 1H NMR (CDCl3)  1.66–2.44 (m, 11H), 2.68 (s, 2H); 
13
C NMR (125.7 MHz, 
CDCl3)  30.43 (d, J = 10.1 Hz), 37.94 (d, J = 2.4 Hz), 41.55 (d, J = 17.8 Hz), 42.05 (d, J = 20.2 
Hz), 47.05 (d, J = 10.1 Hz), 90.18 (d, J = 185.7 Hz), 214.92 (d, J = 1.9 Hz).  Step 3.  To a 
solution of 50 (800 mg, 4.8 mmol) in EtOH (40 mL) was added pyridine (564 mg, 7.1 mmol) 
followed by methoxylamine hydrochloride (477 mg, 5.7 mmol).  The reaction mixture was 
stirred at rt for 2 h, concentrated in vacuo, and diluted with water (10 mL).  After filtration, O-
methyl 5-fluoro-2-adamantanone oxime (51) was obtained as a white solid (773 mg, 82%). Mp 
70–72 °C; 1H NMR (CDCl3)  1.70–2.06 (m, 10H), 2.37 (d, J = 2.0 Hz, 1H), 2.78 (s, 1H), 3.69 
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(s, 1H), 3.82 (s, 3H); 
13
C NMR (CDCl3)  30.78 (d, J = 10.0 Hz), 30.96 (d, J = 9.6 Hz), 36.08 (d, 
J = 2.4 Hz), 37.50 (d, J = 1.9 Hz), 37.90 (d, J = 10.6 Hz), 41.45 (d, J = 18.7 Hz), 41.74 (d, J = 
17.3 Hz), 42.69 (d, J = 18.7 Hz), 61.12, 91.23 (d, J = 185.2 Hz), 162.81 (d, J = 2.4 Hz).  Step 4.  
A solution of 51 (918 mg, 4.66 mmol) and 37 (1.19 g, 6.99 mmol) in cyclohexane (40 mL) and 
CH2Cl2 (20 mL) was treated with ozone according to the method of Dong et al.
28
  After removal 
of solvents, the crude product was purified by crystallization from EtOH to afford trans,cis-5-
fluoroadamantane-2-spiro-3'-8'-methoxycarbonylmethyl- 1',2',4'-trioxaspiro[4.5]decane (52) 
(450 mg, 27%, 3:1 mixture of diastereomers) as a white solid.  Mp 126–128 °C; 1H NMR 
(CDCl3) δ 1.23–1.28 (m, 2H), 1.55–1.95 (m, 15H), 2.18–2.23 (m, 7H), 3.67 (s, 3H); 
13
C NMR 
(CDCl3) δ 29.40 (d, J = 10.1 Hz), 29.80, 32.99, 33.14 (d, J = 1.9 Hz), 33.75, 38.76 (d, J = 11.4 
Hz), 39.20 (d, J = 19.7 Hz), 40.54, 41.97 (d, J = 17.3 Hz), 51.49, 91.20 (d, J = 184.3 Hz), 
109.01, 109.46, 173.12.  Step 5.  To a solution of 52 (450 mg, 1.27 mmol) in EtOH (10 mL) was 
added a solution of NaOH (152 mg, 3.81 mmol) in water (4 mL).  The mixture was stirred for 4 
h at 55 °C and evaporated to give an oil.  The residue was cooled to 0 °C and treated with 1 M 
aq. HCl (4 mL) and CH2Cl2 (30 mL).  After separation of the organic layer, the aqueous phase 
was extracted with CH2Cl2 (2 x 20 mL). The combined organic phase was washed with saturated 
aqueous NaHCO3 (2 x 20 mL) and brine (20 mL), dried over MgSO4, filtered, and evaporated to 
give 23 (266 mg, 62%, 5:1 mixture of diastereomers) as a white solid.  Mp 147–149 °C; 1H 
NMR (CDCl3) δ 1.24–1.32 (m, 2H), 1.55–1.93 (m, 15H), 2.19-2.28 (m, 7H); 
13
C NMR (CDCl3) 
δ 29.40 (d, J = 9.6 Hz), 29.74, 32.78, 33.15 (d, J = 1.9 Hz), 33.73, 38.77 (d, J = 10.6 Hz), 39.21 
(d, J = 19.7 Hz), 40.47, 41.97 (d, J = 17.3 Hz), 91.23 (d, J = 184.7 Hz), 108.93, 109.53, 178.80.  
Anal. (C18H25FO5) C, H. 
cis-6-Fluoroadamantane-2-spiro-3'-8'-carboxymethyl-1',2',4'-trioxaspiro[4.5] decane (24).  
Step 1.  Sodium borohydride (1.11 g, 29.2 mmol) was added portion-wise to a ice-cold solution 
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of 2,6-adamantandione monoethylene ketal (53)
33
 (1.74 g, 8.35 mmol) in MeOH (100 mL) at 
such a rate as to keep the internal temperature below 10 °C.  The reaction mixture was allowed to 
warm to rt and stirred for 24 h.  After quenching with water (10 mL), the solvents were removed 
in vacuo and the residue was partitioned between CH2Cl2 (80 mL) and water (60 mL).  After 
phase separation, the aq. phase was extracted with CH2Cl2 (3 x 40 mL).  The combined organic 
phases were dried over MgSO4, filtered, and concentrated in vacuo to afford 6-hydroxy-2-
adamantanone monoethylene ketal (54) (1.6 g, 91%) as a white solid.  Mp 128-130 °C; 
1
H NMR 
(CDCl3) δ 1.62–2.08 (m, 13H), 3.80 (s, 1H), 3.95 (s, 4H); 
13
C NMR (CDCl3) δ 28.21, 33.29, 
33.39, 35.24, 35.83, 64.19, 73.55, 110.95.  Step 2.  To a solution of 54 (808 mg, 3.8 mmol) in 
CH2Cl2 (40 mL) was added bis(2-methoxyethyl)aminosulfur trifluoride (850 mg, 3.8 mmol) and 
the reaction mixture was stirred at rt for 24 h before quenching with water (30 mL).  The 
aqueous phase was extracted with CH2Cl2 (2 x 40 mL) and the combined organic phases were 
washed with saturated aqueous NaHCO3 (2 x 30 mL) and brine (30 mL), dried over MgSO4, and 
concentrated in vacuo to afford crude 6-fluoro-2-adamantanone monoethylene ketal (55) (540 
mg, 66%) as a white solid.  Mp 45-47 °C; 
1
H NMR (CDCl3) δ 1.59 (d, J = 12.7 Hz, 2H), 1.74 (s, 
2H), 1.79 (d, J = 12.7 Hz, 2H), 2.01–2.11 (m, 6H), 3.94 (s, 4H), 4.59 (d, J = 50.8 Hz, 1H); 13C 
NMR (CDCl3) δ 28.40 (J = 1.0 Hz), 31.34 (J = 18.2 Hz), 32.37 (J = 8.7 Hz), 34.92 (J = 1.4 Hz), 
35.45, 64.11, 94.17 (J = 179.5 Hz), 110.29.  Step 3.  To a solution of 55 in 2:1 acetone:water (12 
mL) was added conc. HCl (4 mL) and the reaction mixture was stirred at 70 °C for 1 h.  After 
removal of the solvents in vacuo, CH2Cl2 (6 mL) and water (6 mL) were added. After phase 
separation, the aq. phase was extracted with CH2Cl2 (2 x 4 mL). The combined organic phases 
were dried over MgSO4 and concentrated in vacuo to afford 6-fluoro-2-adamantanone (56) (55 
mg, 86%) as a white solid.  Mp 230–232 °C; 1H NMR (CDCl3) δ 1.81–2.49 (m, 12H), 4.85 (dt, J 
= 49.8, 3.4 Hz, 1H); 
13
C NMR (CDCl3) δ 31.73 (J = 18.7 Hz), 32.68 (J = 1.4 Hz), 36.42 (J = 8.6 
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Hz), 44.67 (J = 1.9 Hz), 45.48, 92.72 (J = 180.9 Hz), 215.95.  Step 4.  To a solution of 56 (336 
mg, 2.0 mmol) in EtOH (25 mL) was added pyridine (316 mg, 3.0 mmol) followed by 
methoxylamine hydrochloride (200 mg, 2.4 mmol). The reaction mixture was stirred at rt for 6 h, 
concentrated in vacuo, and diluted with CH2Cl2 (50 mL) and water (50 mL).  The organic phase 
was separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL).  The combined 
organic phases were washed with 1 M HCl (30 mL), saturated aqueous NaHCO3 (30 mL), and 
brine (30 mL) and dried over MgSO4. Removal of the solvents in vacuo afforded O-methyl 6-
fluoro-2-adamantanone oxime (57) (370 mg, 94%, 1:1 mixture of diastereomers) as a white 
solid.  Mp 70-72 °C; 
1
H NMR (CDCl3) δ 1.61–2.49 (m, 11H), 3.41–3.44 (m, 1H), 3.81 (s, 1.5H), 
3.82 (s, 1.5H), 4.71–4.82 (m, 1H); 13C NMR (CDCl3) δ 31.24 (J = 1.0 Hz), 32.30 (J = 18.2 Hz), 
32.36 (J = 18.2 Hz), 34.36, 35.00, 35.28 (J = 8.6 Hz), 36.53 (J = 8.6 Hz), 60.96, 44.67 (J = 1.9 
Hz), 45.48, 92.72 (J = 180.9 Hz), 215.95.  Step 5.  A solution of 57 (370 mg, 1.9 mmol) and 37 
(479 mg, 2.8 mmol) in cyclohexane (30 mL) and CH2Cl2 (60 mL) was treated with ozone 
according to the method of Dong et al.
28
  After removal of solvents in vacuo, the crude product 
was purified by crystallization from cold EtOH to afford cis-6-fluoroadamantane-2-spiro-3'-8'-
methoxycarbonylmethyl-1',2',4'-trioxaspiro[4.5]decane (58) (250 mg, 38%) as a white solid.  Mp 
114–116 °C; 1H NMR (CDCl3) δ 1.23–1.30 (m, 2H), 1.58–2.13 (m, 19H), 2.22 (d, J = 7.3 Hz, 
1H), 3.67 (s, 3H), 4.59 (d, J = 50.8 Hz); 
13
C NMR (CDCl3) δ 28.51 (J = 1.0 Hz), 28.57, 29.84 (J 
= 3.8 Hz), 31.02 (J = 18.2 Hz), 31.43 (J = 18.2 Hz), 32.38 (J = 4.3 Hz), 32.45 (J = 4.3 Hz), 
33.07, 33.83 (J = 2.9 Hz), 34.86 (J = 1.4 Hz), 35.43, 40.57, 51.46, 93.90 (J = 179.5 Hz), 108.74, 
110.32, 173.15.  Step 6.  To a solution of 58 (250 mg, 0.7 mmol) in EtOH (12 mL) was added a 
solution of NaOH (85 mg, 2.1 mmol) in water (3 mL).  The mixture was stirred at 60 °C for 3 h 
and concentrated in vacuo.  The residue was cooled to 0 °C and treated with 1 M aq. HCl (5 mL) 
and H2O (10 mL).  The precipitate was collected by filtration and dried in vacuo at 40 °C to 
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afford 24 (237 mg, 99%) as a white solid.  Mp 144–146 °C; 1H NMR (CDCl3) δ 1.24–1.32 (m, 
2H), 1.59–2.10 (m, 19H), 2.27 (d, J = 6.8 Hz, 1H), 4.60 (d, J = 50.8 Hz); 13C NMR (CDCl3) δ 
28.52, 28.57, 29.78 (J = 3.4 Hz), 30.99 (J = 18.2 Hz), 31.41 (J = 18.2 Hz), 32.37 (J = 3.8 Hz), 
32.44 (J = 3.8 Hz), 32.85, 33.80 (J = 2.9 Hz), 34.83, 35.40, 40.44, 93.93 (J = 179.0 Hz), 108.66, 
110.39, 178.46.  Anal. (C18H25FO5) C, H. 
cis-6,6-Difluoroadamantane-2-spiro-3'-8'-carboxymethyl-1',2',4'-trioxaspiro[4.5] 
decane (25).  Step 1.  To a solution of 2,6-adamantanedione monoethylene ketal (53)
33
 (1.17 g, 
5.6 mmol) in CH2Cl2 (85 mL) was added bis(2-methoxyethyl)aminosulfur trifluoride (2.27 g, 
10.3 mmol) and the reaction mixture was stirred at rt for 24 h before quenching with water (50 
mL).  The aqueous phase was separated and extracted with CH2Cl2 (2 x 40 mL).  The combined 
organic layers were washed with saturated aqueous NaHCO3 (2 x 40 mL) and brine (40 mL), 
dried over MgSO4, filtered, and concentrated in vacuo to give a residue that was purified by flash 
chromatography (sg, 40:1 hexane:ethyl acetate) to afford 6,6-difluoro-2-adamantanone 
monoethylene ketal (59) (1.10 g, 85%) as a colorless solid.  Mp 76–78 °C; 1H NMR (CDCl3) δ 
1.77 (s, 2H), 1.87-1.90 (d, J = 12.7 Hz, 4H), 2.00-2.02 (d, J = 12.2 Hz, 4H), 2.11 (s, 2H), 3.95 (s, 
4H); 
13
C NMR (CDCl3) δ 30.76 (J = 3.8 Hz), 34.58 (J = 21.6 Hz), 34.87, 64.37, 109.31, 124.43 
(J = 246.6 Hz).  Step 2.  To a solution of 59 (1.1 g, 4.78 mmol) in 5:1 acetone:water (96 mL) 
was added conc. HCl (40 mL) and the reaction mixture was heated to 70 °C gradually.  After the 
disappearance of the starting material as determined by GC-MS (0.5 h), the mixture was cooled 
to 0 °C and NaHCO3 was added to adjust the pH to 7.  After CH2Cl2 (80 mL) was added to the 
mixture, the organic layer was separated.  The aq. phase was extracted with CH2Cl2 (3 x 50 mL).  
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to 
afford 6,6-difluoro-2-adamantanone (60) as a white solid (760 mg, 85%).  Mp 252–255 °C; 1H 
NMR (CDCl3) δ 2.01 (d, J = 12.7 Hz, 4H), 2.29 (d, J = 12.7 Hz, 4H), 2.35 (s, 2H), 2.53 (s, 2H); 
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13
C NMR (CDCl3) δ 34.86 (J = 3.8 Hz), 35.06 (J = 22.1 Hz), 44.47, 123.15 (J = 247.6 Hz), 
214.28.  Step 3.  To a solution of 60 (760 mg, 4.1 mmol) in EtOH (50 mL) was added pyridine 
(483 mg, 6.1 mmol) followed by methoxylamine hydrochloride (409 mg, 4.9 mmol).  The 
reaction mixture was stirred at rt for 6 h, concentrated in vacuo, and diluted with CH2Cl2 (50 
mL) and water (50 ml).  The organic phase was separated, and the aqueous layer was extracted 
with CH2Cl2 (3 x 50 mL).  The combined organic phases were washed with 1 M HCl (40 mL), 
saturated aqueous NaHCO3 (40 mL) and brine (40 mL), and dried over MgSO4. Removal of the 
solvent in vacuo afforded O-methyl 6,6-difluoro-2-adamantanone oxime (61) (760 mg, 87%) as a 
white solid.  Mp 114-116 °C; 
1
H NMR (CDCl3) δ 1.80–1.89 (m, 4H), 2.09–2.18 (m, 4H), 2.30 (s, 
1H), 2.52 (s, 1H), 3.46 (s, 1H), 3.82 (s, 1H); 
13
C NMR (CDCl3) δ 27.22, 33.59 (J = 3.4 Hz), 
34.06, 34.87 (J = 3.4 Hz), 35.53 (J = 3.4 Hz), 61.10, 123.90 (J = 247.1 Hz), 162.97.  Step 4.  A 
solution of 61 (460 mg, 2.1 mmol) and 37 (546 mg, 3.2 mmol) in cyclohexane (30 mL) and 
CH2Cl2 (6 mL) was treated with ozone according to the method of Dong et al.
28
  After removal 
of solvents in vacuo, the crude product was purified by crystallization from cold EtOH to afford 
cis-6,6-difluoroadamantane-2-spiro-3'-8'- methoxycarbonylmethyl-1',2',4'-trioxaspiro[4.5]decane 
(62) (322 mg, 41%) as a white solid. mp 129–131 °C; 1H NMR (CDCl3) δ 1.20-1.29 (m, 2H), 
1.69-2.14 (m, 19H), 2.23 (d, J = 6.8 Hz, 2H), 3.70 (s, 3H); 
13
C NMR (CDCl3) δ 30.65 (J = 3.8 
Hz), 30.68 (J = 3.4 Hz), 32.99, 34.11 (J = 21.6 Hz), 34.52 (J = 21.6 Hz), 34.57, 40.49, 51.47, 
108.94, 109.08, 123.94 (J = 247.1 Hz), 173.11.  Step 5.  To a solution of 62 (322 mg, 0.87 
mmol) in EtOH (8 mL) was added a solution of NaOH (104 mg, 2.6 mmol) in water (3 mL).  
The mixture was stirred at rt for 4 h and evaporated to give an oil.  After the residue was treated 
with 1 M HCl to lower the pH to 3, the aqueous phase was extracted with CH2Cl2 (3 x 50 mL).  
The combined extracts were dried over MgSO4, filtered, and evaporated to afford 25 (277 mg, 
89%) as a white solid.  Mp 148–150 °C; 1H NMR (CDCl3) δ 1.29-1.37 (m, 2H), 1.75-2.20 (m, 
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19H), 2.23 (d, J = 6.8 Hz, 2H); 
13
C NMR (125.7 MHz, CDCl3) δ 29.72, 30.67 (J = 3.8 Hz), 30.70 
(J = 3.8 Hz), 32.79, 33.73, 34.12 (J = 21.6 Hz), 34.54 (J = 21.6 Hz), 34.58, 40.53, 108.87, 
109.16, 123.96 (J = 247.1 Hz), 179.20.  Anal. (C18H24F2O5) C, H. 
Adamantane-2-spiro-3'-8'-carboxymethyl-1',2'-dioxaspiro[4.5]decane (26).  Step 1.  To a 
solution of I2 (0.254 g, 1.0 mmol) and 50% H2O2 (4.5 ml, 40 mmol) in MeOH (50 mL) was 
added 37 (1.70 g, 10 mmol).  After the mixture was stirred at rt for 24 h, it was concentrated in 
vacuo and the residue was partitioned between CH2Cl2 (30 mL) and water (30 mL).  The aq. 
layer was extracted with CH2Cl2 (2 x 30 mL).  The combined extracts were washed with water, 
brine, dried over MgSO4, filtered, and concentrated to afford methyl 2-(4-hydroperoxy-4-
methoxycyclohexyl)acetate as a 1:1 mixture of diastereomers (2.15 g, 99%) which was used 
immediately in the next step.
 
 
1
H NMR (CDCl3) δ 0.92–2.46 (m, 11H), 3.30 (s, 1.5H), 3.34 (s, 
1.5H), 3.70 (s, 3H), 7.42 (s, 0.5H), 7.52 (s, 0.5H).  Step 2.  To a solution of the unpurified 
methyl 2-(4-hydroperoxy-4-methoxycyclohexyl)acetate (2.15 g, 9.86 mmol) in DMF (100 mL) 
at 0 °C was added Et3N (4.5 ml, 32 mmol) followed by Et3SiOTf (2.54 ml, 12 mmol).  The 
reaction mixture was stirred at rt for 24 h and then diluted with ice-cold hexane (100 mL) and 
ice-water (100 mL).  The organic layer was separated and the aq. layer was extracted with 
hexane (3 x 100 mL).  The organic extracts were combined, dried over MgSO4, and concentrated 
to afford methyl 2-[4-methoxy-4-(triethylsilylperoxy)cyclohexyl]acetate (63) as a 1:1 mixture of 
diastereomers (3.02 g, 92%) which was used immediately in the next step.
 
 
1
H NMR (CDCl3) δ 
0.68–0.80 (m, 6H), 0.94–1.08 (m, 9H), 0.84–2.44 (m, 11H), 3.26 (s, 1.5H), 3.29 (s, 1.5H), 3.67 
(s, 3H).  Step 3.  To a solution of 63 (3.02 g, 9.10 mmol) in CH2Cl2 (50 ml) at –78 °C was added 
2-methyleneadamantane
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 (64) (0.67 g, 4.53 mmol) followed by 1M SnCl4 in CH2Cl2 (10 mL, 10 
mmol).  The resulting mixture was stirred at –78 °C for 30 min and then kept at –30 °C 
overnight. The reaction mixture was allowed to warm to -3 °C and quenched with ice-water (50 
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ml).  After separation of the organic layer, the aqueous layer was extracted with CH2Cl2 (2 x 50 
ml).  The combined extracts were washed with water (50 mL) and brine (50 mL), dried over 
MgSO4, filtered, and concentrated in vacuo.  Purification by chromatography (sg, 0 to 10 % ether 
in hexane) afforded adamantane-2-spiro-3'-8'-methoxycarbonylmethyl-1',2'-
dioxaspiro[4.5]decane (65) as a colorless solid (0.60 g, 40%).  Mp 119–120 °C; 1H NMR 
(CDCl3) δ 1.24–1.36 (m, 2H), 1.44–1.96 (m, 17H), 1.95–2.02 (m, 2H), 2.06–2.14 (m, 2H), 2.13 
(s, 2H), 2.20 (d, J = 7.5Hz, 2H), 3.66 (s, 3H); 
13
C NMR (CDCl3) δ 26.44, 26.99, 29.07, 33.45, 
34.93, 35.64, 36.24, 37.21, 41.17, 51.42, 55.47, 84.02, 88.71, 173.47.  Step 4.  To a solution of 
65 (0.45 g, 1.35 mmol) in EtOH (20 mL) was added 15% aq. KOH (2 mL) and the resulting 
mixture was stirred at 60 °C for 20 h.  The solution was concentrated to ~5 mL and the residue 
was diluted with water (10 mL) and acidified with acetic acid (5 mL).  The precipitate was 
collected by filtration, washed with cold water, and dried in vacuo at 40 °C to afford 26 as a 
colorless solid (0.40 g, 93%).  Mp 184–185 °C; 1H NMR (CDCl3) δ 1.27–1.40 (m, 2H), 1.42–
1.96 (m, 17H), 1.95–2.04 (m, 2H), 2.06–2.14 (m, 2H), 2.13 (s, 2H), 2.24 (d, J = 7.5Hz, 2H), 
11.14 (brs, 1H); 
13
C NMR (CDCl3) δ 26.44, 26.99, 29.00, 33.26, 33.45, 34.90, 35.64, 36.24, 
37.20, 41.04, 55.46, 83.98, 88.75, 178.74.  Anal. (C19H28O4) C, H. 
Adamantane-2-spiro-2'-8'-carboxymethyl-1',4'-dioxaspiro[4.5]decane (27).  p-
Toluenesulfonic acid monohydrate (260 mg, 1.37 mmol) was added to a solution of 2-
hydroxymethyl-2-adamantanol (66)
37
 (1.22 g, 6.69 mmol) and 2-(4-oxocyclohexyl)acetic acid 
(67) (1.14 g, 7.29 mmol) in CH2Cl2 (200 mL).  The reaction mixture was stirred at rt for 4 h, 
washed with water (100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in 
vacuo.  The crude product was purified by crystallization from aq. MeOH to afford 27 as a white 
solid (1.69 g, 79%, 1.3:1 mixture of isomers based on the 
1
H NMR singlets at 3.84 and 3.88).  
Mp 133–135 °C; 1H NMR (CDCl3) δ 1.25–1.85 (m, 21H), 2.18 (q, 2H), 2.26 (d, J = 6.8 Hz, 
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0.78H), 2.29 (d, J = 6.8 Hz, 1.11H), 3.84 (s, 0.87H), 3.88 (s, 1.13H); 
13
C NMR (CDCl3) δ 26.67, 
26.70, 26.79, 26.93, 30.01, 30.05, 33.08, 33.46, 33.64, 35.82, 35.91, 35.96, 36.33, 37.25, 37.34, 
37.41, 40.66, 40.74, 72.14, 72.32, 84.33, 84.48, 108.35, 108.46, 178.79, 178.89.  Anal. 
(C19H28O4) C, H. 
 
Evaluation of activity against F. hepatica.  All animal studies
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 presented here were approved 
by regulatory authorities following Swiss National regulations. Metacercariae of F. hepatica 
were purchased from Baldwin Aquatics (Monmouth, OR, USA).  Female Wistar rats (weight: 
~100 g) were purchased from Harlan (Horst, The Netherlands). Animals were kept in groups of 4 
in Macrolon cages in environmentally-controlled conditions (temperature: ~25°C; humidity: 
~70%; 12 h light/dark cycle) and acclimatized for 1 week. Rats were infected with ~20 
metacercariae each. They had free access to water and rodent diet. At eight weeks post-infection, 
rats were treated with single 50-100 mg/kg oral doses of target compounds prepared as 
suspensions in 7% (v/v) Tween 80 and 3% (v/v) EtOH.  At day 6 post-treatment, rats were 
sacrificed by CO2 and adult flukes were recovered from the bile ducts and livers. Target 
compound efficacies were evaluated by comparing the mean total worm burdens of treated and 
untreated control rats.  Statistical significance (at a significance level of 5%) was calculated 
using the Kruskal Wallis test (Statsdirect v 2.4.5; Cheshire, United Kingdom). 
Supporting Information Available:  Elemental analysis for 6-8, 10, 14, and 16-27.  This 
material is available free of charge via the Internet at http://pubs.acs.org.  
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Table 1.  Worm burden reductions in adult F. hepatica harbored in rats following the 
administration of ozonides 1 to 11 at single oral doses of 100 mg/kg. 
OO
O
O
R
 
Compd R Worm Burden 
Reduction (%) 
Cures 
 
    
Control ------ ------ 0/12 
AS
a,b
 ------ 30 2/5 
1
c
 OH 100
e
 10/10 
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2  OMe 99
e
 2/3 
3
d
 OEt 36 2/4 
4  NHOH 34 0/3 
5  NHC=NH(NH2) 0 0/4 
6  NHSO2CH3 100
e
 4/4 
7  NHCH2COOH 86
e
 2/4 
8  NH(CH2)2SO3Na 0 0/4 
9  NH2 7 0/3 
10  NHNH2 12 0/3 
11  N(CH2CH2)2NH 0 0/4 
 
a
AS = artesunate 
b
data from Keiser et al.
13
  
c
data from Keiser et al.
12
  
d
tested at 50 mg/kg 
e
p < 0.05 from the Kruskal-Wallis test comparing the medians of the responses between the 
treatment and control groups  
 
 
 
 
 
Table 2.  Worm burden reductions in adult F. hepatica harbored in rats following the 
administration of ozonides 12 to 20 at single oral doses of 100 mg/kg. 
OO
O
R
12-16
N
COONa
OO
O COOH
COOH
COOH
17 18 19 20  
Compd R Worm Burden 
Reduction (%) 
Cures 
 
    
12  COOH 52
a
 1/4 
 41 
13  CH2CH2COOH 14 0/5 
14  CH(COOH)2 0 0/4 
15  CH2NHCOCOOH 14 0/3 
16  CH2PO(OEt)OK 16 0/3 
17  ------ 0 0/3 
18  ------ 95
a
 2/3 
19  ------ 46 0/3 
20  ------ 90
a
 2/3 
 
a
p < 0.05 from the Kruskal-Wallis test comparing the medians of the responses between the 
treatment and control groups  
 
 
 
 
 
 
 
 
 
 
Table 3.  Worm burden reductions in adult F. hepatica harbored in rats following the 
administration of ozonides 21 to 27 at single oral doses of 100 mg/kg. 
H
F
OO
O COOH
F F
F
21 22 23 24 25
OX
Y COOH
26, X = O, Y = CH2
27, X = CH2, Y = O  
Compd Worm Burden Cures 
 42 
Reduction (%)  
   
21  0 0/3 
22  51 0/3 
23  80
a
 2/3 
24  76
b
 1/3 
25  80
a
 0/3 
26 7 0/3 
27  0 0/3 
 
a
p < 0.05 from the Kruskal-Wallis test comparing the medians of the responses between the 
treatment and control groups  
b
p = 0.051  
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